3 results
Approved WMOPending
Primary Objectives:* To compare overall survival (OS) of patients who receive NKTR-102given once every 21 days (q21d) to patients who receive Treatment ofPhysician*s Choice (TPC) selected from the following list of seven singleagentintravenous…
Approved WMORecruiting
• To assess the tolerability and safety of the investigational medicinal product
Approved WMOPending
The objective of this first-in-human study is to evaluate the safety, feasibility and efficacy of Re-Cellularization via Electroporation Therapy (ReCET) by the (Endogenex system) combined with (GLP-1 receptor agonist) in subjects with insulin…